• Our extensive knowledge on the disovery and development of therapeutic monoclonal antibodies is, in addition to our services, extensively used for the strength of our product pipeline.
   
• Bioceros is building a pipeline of promising early-stage proprietary therapeutic monoclonal antibodies including targets in oncology and autoimmune disease. The company employs its validated technology platforms and preclinical development expertise to design and to generate effective humanized monoclonal antibodies.

• Bioceros is actively seeking early-stage monoclonal antibody product candidates in the field of cancer and autoimmuno disease for either in-licensing or co-development.
  • An example of one of our co-developed monoclonal antibodies is the Cripto-1 cancer monoclonal antibody.

• If you want to learn more about this opportunity, please contact:
  
  

Louis Boon, Ph.D.
Chief Scientific Officer
Tel.: +31 30 253 7521 or +31 6 25026350
Email: l.boon@bioceros.com